These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17497760)

  • 21. Human variability in the renal elimination of foreign compounds and renal excretion-related uncertainty factors for risk assessment.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2004 Feb; 42(2):275-98. PubMed ID: 14667473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach.
    Chiu WA; Okino MS; Evans MV
    Toxicol Appl Pharmacol; 2009 Nov; 241(1):36-60. PubMed ID: 19660485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validity and reliability of in vitro systems in safety evaluation.
    Paine AJ
    Environ Toxicol Pharmacol; 1996 Oct; 2(2-3):207-12. PubMed ID: 21781729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathion.
    Gentry PR; Hack CE; Haber L; Maier A; Clewell HJ
    Toxicol Sci; 2002 Nov; 70(1):120-39. PubMed ID: 12388841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Situations with enhanced chemical risks due to toxicokinetic and toxicodynamic factors.
    Dybing E; Søderlund EJ
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S27-30. PubMed ID: 10597610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2003 Feb; 41(2):201-24. PubMed ID: 12480298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform.
    Liao KH; Tan YM; Conolly RB; Borghoff SJ; Gargas ML; Andersen ME; Clewell HJ
    Risk Anal; 2007 Dec; 27(6):1535-51. PubMed ID: 18093051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjustment factors for toluene, styrene and methyl chloride by population modeling of toxicokinetic variability.
    Mörk AK; Jonsson F; Johanson G
    Regul Toxicol Pharmacol; 2014 Jun; 69(1):78-90. PubMed ID: 24613484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A lifestage-specific approach to hazard and dose-response characterization for children's health risk assessment.
    Makris SL; Thompson CM; Euling SY; Selevan SG; Sonawane B
    Birth Defects Res B Dev Reprod Toxicol; 2008 Dec; 83(6):530-46. PubMed ID: 19085945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
    Alexander KP; Newby LK; Cannon CP; Armstrong PW; Gibler WB; Rich MW; Van de Werf F; White HD; Weaver WD; Naylor MD; Gore JM; Krumholz HM; Ohman EM; ;
    Circulation; 2007 May; 115(19):2549-69. PubMed ID: 17502590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing.
    Wetmore BA; Allen B; Clewell HJ; Parker T; Wambaugh JF; Almond LM; Sochaski MA; Thomas RS
    Toxicol Sci; 2014 Nov; 142(1):210-24. PubMed ID: 25145659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling.
    Bouzom F; Walther B
    Fundam Clin Pharmacol; 2008 Dec; 22(6):579-87. PubMed ID: 19049658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach.
    Bokkers BG; Slob W
    Crit Rev Toxicol; 2007 Jun; 37(5):355-73. PubMed ID: 17612951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uncertainty factors for chemical risk assessment. human variability in the pharmacokinetics of CYP1A2 probe substrates.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2001 Jul; 39(7):681-96. PubMed ID: 11397515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative evaluation of dichloroacetic acid kinetics in human--a physiologically based pharmacokinetic modeling investigation.
    Li T; Schultz I; Keys DA; Campbell JL; Fisher JW
    Toxicology; 2008 Mar; 245(1-2):35-48. PubMed ID: 18242812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using Collaborative Cross Mouse Population to Fill Data Gaps in Risk Assessment: A Case Study of Population-Based Analysis of Toxicokinetics and Kidney Toxicodynamics of Tetrachloroethylene.
    Luo YS; Cichocki JA; Hsieh NH; Lewis L; Wright FA; Threadgill DW; Chiu WA; Rusyn I
    Environ Health Perspect; 2019 Jun; 127(6):67011. PubMed ID: 31246107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneity of toxicant response: sources of human variability.
    Aldridge JE; Gibbons JA; Flaherty MM; Kreider ML; Romano JA; Levin ED
    Toxicol Sci; 2003 Nov; 76(1):3-20. PubMed ID: 12883075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.